Journal of addiction medicine · 2025
Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Landis Rachel K, Sheng Flora, Stein Bradley D
Аннотация
IMPORTANCE: Medicaid is an important source of coverage for buprenorphine treatment for opioid use disorder (OUD). The loss of Medicaid coverage through Medicaid unwinding may substantially impact individuals' ability to initiate and continue buprenorphine, but little is known about how Medicaid unwinding is associated with buprenorphine OUD treatment.
OBJECTIVE: Examine the association of Medicaid unwinding overall and by magnitude of unwinding with changes in buprenorphine OUD treatment.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using 2021-2023 national retail pharmacy data on dispensed buprenorphine prescriptions.
EXPOSURE: Magnitude of Medicaid disenrollment in the 6 months after unwinding began.
MAIN OUTCOMES AND MEASURES: Average monthly change in new and ending buprenorphine treatment episodes, defined as starting buprenorphine treatment after 30 days without buprenorphine and ending after 30 days without buprenorphine. Statistical significance was assessed using 95% CI constructed from 2-sample t tests.
RESULTS: Medicaid unwinding was associated with increases in Medicaid buprenorphine episodes ending (+3.0%, 95% CI: -1.1, 7.0, n=+5350) and decreases in new Medicaid episodes (-2.6%, 95% CI: -5.3, 0.1, n=-5756). The greatest changes were in states with the greatest disenrollment (+5.5%, 95% CI: 0.8, 10.1; n=+2320 for episodes ending and -3.9%, 95% CI: -7.3, -0.6; n=-1843 for episodes starting). Changes in Medicaid-covered episodes were not offset by other payers: among all payers, we observed an increase in episodes ending (+2.7%, 95% CI: 1.9, 3.4, n=+10,300) and a negligible increase in new episodes (+0.1%, 95% CI: -0.7, 1.0, n=+570).
CONCLUSIONS AND RELEVANCE: Medicaid unwinding may have resulted in substantial disruptions to buprenorphine treatment.
OBJECTIVE: Examine the association of Medicaid unwinding overall and by magnitude of unwinding with changes in buprenorphine OUD treatment.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using 2021-2023 national retail pharmacy data on dispensed buprenorphine prescriptions.
EXPOSURE: Magnitude of Medicaid disenrollment in the 6 months after unwinding began.
MAIN OUTCOMES AND MEASURES: Average monthly change in new and ending buprenorphine treatment episodes, defined as starting buprenorphine treatment after 30 days without buprenorphine and ending after 30 days without buprenorphine. Statistical significance was assessed using 95% CI constructed from 2-sample t tests.
RESULTS: Medicaid unwinding was associated with increases in Medicaid buprenorphine episodes ending (+3.0%, 95% CI: -1.1, 7.0, n=+5350) and decreases in new Medicaid episodes (-2.6%, 95% CI: -5.3, 0.1, n=-5756). The greatest changes were in states with the greatest disenrollment (+5.5%, 95% CI: 0.8, 10.1; n=+2320 for episodes ending and -3.9%, 95% CI: -7.3, -0.6; n=-1843 for episodes starting). Changes in Medicaid-covered episodes were not offset by other payers: among all payers, we observed an increase in episodes ending (+2.7%, 95% CI: 1.9, 3.4, n=+10,300) and a negligible increase in new episodes (+0.1%, 95% CI: -0.7, 1.0, n=+570).
CONCLUSIONS AND RELEVANCE: Medicaid unwinding may have resulted in substantial disruptions to buprenorphine treatment.